Junior Consumer Support Navigator

The Trade Desk brings granular healthcare measurement into media optimization. The Trade Desk Expands Pharma Ad Measurement Healthcare advertisers are increasingly looking to connect media exposure with real-world outcomes rather than relying on campaign-level performance reports. The Trade Desk is expanding integrations with healthcare analytics providers Veeva Crossix and IQVIA Digital to bring more granular measurement signals into programmatic media decisioning, allowing pharmaceutical advertisers to use campaign insights while campaigns are still running. For pharmaceutical marketers, knowing that a campaign performed well is only part of the measurement challenge. The harder question is determining which audiences, devices, geographies and media environments contributed to that performance - and then acting on those signals quickly. The Trade Desk is attempting to close that gap through expanded integrations with Veeva Crossix and IQVIA Digital, bringing specialized healthcare measurement closer to the platform's media optimization and bidding workflows. Traditionally, pharma analytics has often operated alongside media buying platforms. Advertisers could evaluate campaign results and identify optimization opportunities, but applying those insights to an active media campaign could require additional processes. The expanded integrations are designed to shorten that feedback loop. For example, a pharmaceutical advertiser could examine audience quality by site, geography or device, connect media exposure with metrics such as new-to-brand prescriptions (NBRx), and use those signals to inform ongoing media allocation. Crossix is expanding its in-platform optimization capabilities within The Trade Desk. Advertisers can currently optimize campaigns around Audience Quality (AQ) and cost per target reach, while Gross NBRx optimization is planned for the fourth quarter. A weighted KPI capability is also expected in Q4, allowing advertisers to combine Crossix Audience Quality and Gross Conversion data when optimizing toward multiple campaign outcomes. That development reflects a broader movement in programmatic advertising toward outcome-based optimization. Rather than treating impressions or reach as the final measurement layer, advertisers are increasingly looking for signals that connect media exposure to business or downstream outcomes. IQVIA Digital is taking a somewhat different role by expanding the granularity of performance measurement. The company plans to introduce AQ measurement across individual sites, geographies and device types, alongside new-to-brand prescription measurement. The distinction matters for media buyers managing large programmatic campaigns. A campaign may generate strong aggregate results while performance varies considerably across individual supply environments or audience segments. More granular measurement can potentially give traders and automated systems additional signals for deciding where future impressions should be purchased. The Trade Desk also supports multi-provider HCP decisioning, allowing advertisers to extend National Provider Identifier (NPI) reach across multiple healthcare data providers. The objective is to give pharma advertisers additional scale while maintaining healthcare-specific data controls. The development places The Trade Desk within a specialized part of the programmatic ecosystem where privacy, data governance and measurement complexity are particularly important. Healthcare advertising cannot simply apply consumer advertising models without accounting for sensitive data and regulatory requirements. The bigger shift is toward bringing measurement and activation closer together. Instead of waiting until a campaign ends to determine what worked, advertisers can increasingly feed validated performance signals back into media decisioning while campaigns remain active. For enterprise pharma teams, the value will ultimately depend on data quality, measurement methodology, interoperability and the ability to translate healthcare outcomes into reliable optimization signals. But the direction is clear: specialized healthcare analytics is becoming increasingly connected to the systems responsible for buying and optimizing media. Market landscape. Programmatic advertising is evolving from impression-based optimization toward increasingly sophisticated outcome and audience-quality signals. This is particularly visible in verticals such as healthcare, where advertisers need specialized datasets and measurement methodologies. The Trade Desk's integrations with Crossix and IQVIA Digital illustrate a broader trend toward closed-loop media measurement: data is collected from campaign activity, translated into performance signals and returned to the buying environment for optimization. Large advertising ecosystems including Google, Amazon and Microsoft are also investing in automated bidding, measurement and first-party data capabilities. Specialist healthcare providers add another layer by supplying domain-specific signals that general-purpose advertising platforms may not provide. For pharmaceutical advertisers, interoperability will remain central. The ability to combine multiple measurement providers, define campaign-specific KPIs and optimize against meaningful outcomes could reduce the distance between media buying and business measurement, provided privacy and governance requirements are maintained. Top insights. * The Trade Desk is expanding healthcare data integrations with Veeva Crossix and IQVIA Digital to bring measurement signals closer to programmatic media decisioning. * Crossix enables optimization around Audience Quality and cost per target reach, with Gross NBRx and weighted KPI capabilities planned for Q4. * IQVIA Digital is expanding measurement granularity across sites, geographies and devices while adding new-to-brand prescription measurement. * Multi-provider HCP decisioning gives pharmaceutical advertisers additional options for extending NPI reach across healthcare data providers. * The development reflects a broader AdTech shift toward closed-loop optimization, where campaign measurement can directly inform active media buying decisions.

Nilsine Partners LLC makes new investment in Veeva Systems Inc. $VEEV. September 6, 2026 Key points. * Nilsine Partners initiated a position in Veeva Systems during the second quarter, purchasing 14,995 shares valued at approximately $2.66 million. Institutional investors and hedge funds collectively own 88.2% of the company. * Veeva reported strong quarterly results, with revenue rising 17.6% year over year to $927.96 million and EPS of $2.35 surpassing estimates. The company also raised its fiscal 2027 outlook, supported by Vault CRM migrations and growing AI adoption. * Analyst sentiment remains favorable, with a "Moderate Buy" consensus and an average price target of $284.46, although Veeva's premium valuation and recent insider selling remain considerations for investors. * MarketBeat previews top five stocks to own in October. Nilsine Partners LLC acquired a new position in shares of Veeva Systems Inc. (NYSE:VEEV - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 14,995 shares of the technology company's stock, valued at approximately $2,661,000. Other large investors have also modified their holdings of the company. Williams Jones Wealth Management LLC. boosted its holdings in Veeva Systems by 0.4% in the 3rd quarter. Williams Jones Wealth Management LLC. now owns 9,419 shares of the technology company's stock worth $2,806,000 after acquiring an additional 40 shares during the period. Rafferty Asset Management LLC increased its stake in Veeva Systems by 0.7% during the 2nd quarter. Rafferty Asset Management LLC now owns 6,881 shares of the technology company's stock worth $1,982,000 after buying an additional 51 shares during the period. Brown Brothers Harriman & Co. lifted its holdings in Veeva Systems by 8.1% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 719 shares of the technology company's stock worth $214,000 after buying an additional 54 shares in the last quarter. Main Management ETF Advisors LLC boosted its position in Veeva Systems by 1.0% in the 4th quarter. Main Management ETF Advisors LLC now owns 5,481 shares of the technology company's stock valued at $1,224,000 after buying an additional 56 shares during the last quarter. Finally, Root Financial Partners LLC boosted its position in Veeva Systems by 17.1% in the 4th quarter. Root Financial Partners LLC now owns 383 shares of the technology company's stock valued at $85,000 after buying an additional 56 shares during the last quarter. Institutional investors and hedge funds own 88.20% of the company's stock. Here are the key news stories impacting Veeva Systems this week: * Higher outlook and strong operating momentum: Veeva raised its fiscal 2027 outlook as Vault CRM migrations, research-and-development investment and Falcon AI adoption support revenue growth and expanding profitability. This follows a strong latest quarter, in which revenue increased 17.6% year over year to approximately $928 million and adjusted earnings exceeded analyst expectations. * AI adoption is broadening: Regeneron and Biogen have adopted Veeva's AI-powered Vault CRM suite globally. Veeva also introduced Falcon Safety, an agentic AI product designed for biopharmaceutical safety operations. These developments could deepen customer relationships and expand Veeva's role in commercial and safety workflows. * Long-term investor support: Commentary highlights Veeva's recurring-revenue model, Vault CRM migration opportunity and AI expansion as reasons the stock remains attractive for long-term growth investors. Investor Michael Burry has also reportedly remained bullish on Veeva while criticizing Snowflake's valuation. * Valuation and competition remain important considerations: Analysts and portfolio commentary generally support holding VEEV, but warn that market saturation could limit future growth. With the stock trading at a premium earnings multiple after a substantial rally, investors may require continued execution and strong guidance upgrades. * Insider selling may weigh modestly on sentiment: Veeva's exiting president sold 10,000 shares for approximately $2.8 million, representing about 51% of the executive's direct equity stake before the transaction. The sale does not establish a change in business fundamentals, but it can raise caution after the stock's strong advance. Analyst ratings changes. Several research analysts recently commented on VEEV shares. Royal Bank Of Canada boosted their price target on Veeva Systems from $275.00 to $325.00 and gave the stock an "outperform" rating in a research note on Thursday, August 27th. TD Cowen raised their price objective on Veeva Systems from $235.00 to $283.00 and gave the company a "buy" rating in a research note on Monday, August 24th. Citigroup upped their target price on Veeva Systems from $190.00 to $273.00 and gave the company a "neutral" rating in a research report on Friday, August 28th. Zacks Research cut Veeva Systems from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 14th. Finally, Needham & Company LLC raised their price target on shares of Veeva Systems from $270.00 to $310.00 and gave the stock a "buy" rating in a research report on Thursday, August 27th. Nineteen analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Veeva Systems presently has an average rating of "Moderate Buy" and an average price target of $284.46. Discover more Premium stock reports Stocks & Bonds Veeva Systems stock down 3.6%. Shares of Veeva Systems stock opened at $274.02 on Friday. The business has a 50-day moving average price of $220.49 and a 200 day moving average price of $187.95. Veeva Systems Inc. has a fifty-two week low of $148.05 and a fifty-two week high of $310.50. The firm has a market cap of $44.51 billion, a P/E ratio of 45.07, a P/E/G ratio of 1.17 and a beta of 0.97. Veeva Systems (NYSE:VEEV - Get Free Report) last released its earnings results on Wednesday, August 26th. The technology company reported $2.35 EPS for the quarter, topping analysts' consensus estimates of $2.23 by $0.12. Veeva Systems had a return on equity of 14.25% and a net margin of 29.34%.The company had revenue of $927.96 million for the quarter, compared to the consensus estimate of $905.38 million. During the same quarter last year, the business posted $1.99 EPS. Veeva Systems's quarterly revenue was up 17.6% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. As a group, equities research analysts anticipate that Veeva Systems Inc. will post 6.7 earnings per share for the current year. Insiders place their bets. In other Veeva Systems news, insider Thomas Schwenger sold 10,000 shares of the stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $281.33, for a total transaction of $2,813,300.00. Following the sale, the insider directly owned 19,449 shares of the company's stock, valued at approximately $5,471,587.17. This represents a 33.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.60% of the stock is currently owned by insiders. Veeva Systems company profile. Veeva Systems NYSE: VEEV is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint. Veeva's product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Veeva Systems, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veeva Systems wasn't on the list. While Veeva Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.

Veeva Systems is well-positioned for growth due to its strong product portfolio and solid second-quarter fiscal 2027 performance, though market saturation remains a concern. The cloud-based software provider for life sciences has gained 25.7% year-to-date, outpacing the industry's 11.3% and the S&P 500's 10.8% growth. The company's Development Cloud portfolio is driving expansion across clinical development, quality management, and regulatory operations. Vault CRM adoption advanced significantly in Q2, with Veeva securing 12 of the top 20 biopharma CRM commitments. Commercial subscription revenues rose 13% year-over-year to $347.4 million. The company projects 35% growth over the next five years and maintains a market capitalisation of $45.6 billion.